Search the Newsreel

Highlights from Amgen's 2026 Second Quarter Earnings Report

Amgen released its 2026 second quarter earnings report, showcasing strong performance driven by key growth drivers that increased 26% year over year and accounted for nearly 70% of product sales. Chairman and CEO Robert A. Bradway expressed confidence in the company's ability to sustain …

Amgen Inc Stock (AMGN) Closed Up by 3.03% on Aug 4: Key Drivers Unveiled

Amgen Inc (AMGN) stock rose by 3.03% due to strong second-quarter earnings that surpassed expectations, positive interim clinical trial data for a metabolic health candidate, and supportive broader market sentiment for defensive healthcare stocks. The company's robust core product portfolio growth, improved operating margins, …

Amgen Lifts Outlook on Strong Drug Sales, to End Early Development of Obesity Treatment

Amgen has raised its full-year revenue outlook to between $38.2 billion and $39.4 billion due to strong drug sales in the second quarter. However, the biotechnology company also announced it would halt the development of AMG 513, an early-stage obesity treatment that was in …

Amgen second-quarter sales rise 9%, profit tops Street view

Amgen reported a 9% rise in second-quarter sales and adjusted earnings that surpassed analyst expectations, driven by strong demand for drugs like Repatha and Evenity. The company also raised its full-year revenue and profit outlook, despite discontinuing an experimental obesity drug candidate (AMG 513). …

Earnings Flash (AMGN) Amgen Inc. Reports Q2 Revenue $10.05B, vs. FactSet Est of $9.43B

Amgen Inc. reported its second-quarter revenue reached $10.05 billion, surpassing FactSet's estimate of $9.43 billion. This earnings flash indicates strong financial performance for the biotechnology group, exceeding analyst expectations for the quarter. The company also announced lifting its outlook on strong Q2 drug sales, …

Amgen Inc. Cloud Data Breach Exposes Patient PHI in 2026 Cybersecurity Incident Analysis

In July 2026, Amgen Inc. disclosed a cybersecurity incident involving unauthorized access to its third-party-hosted cloud storage systems, resulting in the exfiltration of proprietary data and patient PHI. The company promptly initiated its incident response, engaged forensics experts, and notified the SEC. While the …

Hilltop National Bank Has $1.04 Million Position in Amgen Inc. $AMGN

Hilltop National Bank significantly reduced its stake in Amgen Inc. by 58.3% in the second quarter, now holding 2,860 shares valued at approximately $1.04 million. Despite this, institutional investors collectively own 76.5% of Amgen, which recently declared a quarterly dividend of $2.52 per share. …

Amgen Inc. $AMGN Holdings Cut by CX Institutional

CX Institutional significantly reduced its stake in Amgen Inc. by 32% in Q2, selling 12,252 shares and retaining 25,985 shares valued at $9.41 million. Despite a reported data breach posing a near-term risk, analysts maintain a consensus "Hold" rating with a $357 price target, …

Amgen Inc. (NASDAQ:AMGN) Given Average Recommendation of "Hold" by Brokerages

Amgen Inc. (NASDAQ:AMGN) has received a consensus "Hold" recommendation from thirty research firms, with an average 12-month price target of $357.00. While new medicines and potential expansion into type 2 diabetes offer growth opportunities, the company faces a significant near-term risk from a reported …

Amgen (AMGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Amgen (AMGN) Q2 Earnings and Revenues Surpass Estimates

Amgen (NASDAQ:AMGN) Delivers Strong Q2 CY2026 Numbers, Guides for Strong Full-Year Sales

PRIVACY ALERT: Amgen Under Investigation for Data Breach of Records

Schubert Jonckheer & Kolbe are investigating a data breach at Amgen Inc. that compromised sensitive information, including proprietary data and patient protected health information, from its cloud storage systems in July 2026. Amgen disclosed the "material" breach in an SEC filing but has not …

Amgen Tells SEC Hack Exposed Patient Data, Trade Secrets

Amgen has informed the U.S. Securities and Exchange Commission (SEC) about a June data breach that may have compromised intellectual property, patient information, research and development data, and other confidential business files. The pharmaceutical giant discovered unauthorized activity in July within cloud environments hosted …

Amgen Inc. stock underperforms Monday when compared to competitors

Amgen Inc. (AMGN) stock fell by 1.63% to $378.87 on Monday, underperforming the broader market. This occurred despite a generally favorable trading session where the S&P 500 Index rose 1.48% and the Dow Jones Industrial Average rose 1.32%. This marks the second consecutive day …

California drugmaker Amgen reports theft of patient data in cyber incident

Amgen Inc., a California drugmaker, reported a cyber incident involving the theft of patient health information and proprietary data from third-party cloud servers in July. While the company is still assessing the full impact, it currently does not expect the breach to materially affect …

Amgen Reports Data Breach Exposes Protected Health Info

Amgen Inc. disclosed a data breach to the SEC on July 29, 2026, involving unauthorized access and exfiltration of data from third-party cloud environments. The exposed information includes proprietary company data and patient protected health information. Amgen states that there has been no identified …

Amgen contends with data breach, exposing patient information

Amgen has experienced a data breach affecting its third-party cloud-based systems, compromising both company-owned data and private patient health information. The company has initiated its cybersecurity response plan and believes the incident is "not reasonably likely" to materially impact its financial condition or operations. …

Amgen (AMGN) Discloses Material Cybersecurity Incident Involving Data Exfiltration

Amgen (AMGN) has disclosed a material cybersecurity incident involving unauthorized access to data in third-party cloud environments, resulting in the exfiltration of proprietary data, patient protected health information, and other sensitive information. While the investigation is ongoing, Amgen does not currently believe the incident …

AmGen Announces Cyberattack and Data Breach Involving Patient Data

Amgen Inc. has disclosed a cybersecurity incident where unauthorized actors accessed third-party cloud storage systems, exfiltrating proprietary data and patients’ protected health information. The biopharmaceutical company reported the material incident to the SEC, initiated an investigation with digital forensics experts, and is currently assessing …

Kaléo Announces License Agreement with Amgen for Auto-Injector Technology

Kaléo announced a confidential license agreement with Amgen Inc., granting Amgen access to Kaléo's patented auto-injector technology. This agreement highlights Kaléo's leadership in drug-device technologies and patient-centric auto-injector solutions, though the financial terms were not disclosed. Kaléo specializes in drug-delivery device technology and auto-injector …

3,522 Shares in Amgen Inc. $AMGN Bought by VectorGlobal IAG Inc.

VectorGlobal IAG Inc. recently acquired 3,522 shares of Amgen Inc. (NASDAQ:AMGN) worth approximately $1.24 million, making it a new stakeholder in the biotechnology company. Institutional investors collectively own 76.5% of Amgen's stock, which has seen positive news like an expanded European recommendation for Repatha …

Segall Bryant & Hamill LLC Buys Shares of 23,026 Amgen Inc. $AMGN

Segall Bryant & Hamill LLC has acquired 23,026 shares of Amgen Inc., valued at approximately $8.7 million, marking a new position for the institutional investor. Amgen exceeded its Q1 earnings expectations, reporting $5.15 EPS against an $8.62 billion revenue, and declared a quarterly dividend …

Amgen (AMGN) To Report Earnings Tomorrow: Here Is What To Expect

Amgen (AMGN) is scheduled to report its earnings tomorrow. Analysts expect revenue growth of 2.4% year-on-year, a slowdown from the previous year. The company has a history of meeting or beating Wall Street's revenue estimates, and peer companies like Biogen and Moderna have recently …

Western Wealth Management LLC Increases Stock Position in Amgen Inc. $AMGN

Western Wealth Management LLC significantly increased its stake in Amgen Inc. by 137.5% in the first quarter, now owning 10,207 shares valued at $3.59 million. Other institutional investors have also adjusted their positions in the medical research company. Amgen reported strong Q1 earnings, beating …

Amgen Inc. Revenue Breakdown – FWB:AMG

Amgen Inc. (FWB:AMG) generated 31.29 billion EUR in revenue last year. The Human Therapeutics segment was its top-performing segment, contributing 29.93 billion EUR. The United States was the largest geographical contributor, accounting for 22.49 billion EUR.

Argent Capital Management LLC Trims Stock Position in Amgen Inc. $AMGN

Argent Capital Management LLC reduced its stake in Amgen Inc. by 10.6% in the first quarter, selling 8,963 shares and holding 75,772 shares valued at $26.66 million. Despite this, other institutional investors have increased their holdings, and Amgen announced a quarterly dividend of $2.52 …

Alpine Woods Capital Investors LLC Purchases 4,003 Shares of Amgen Inc. $AMGN

Alpine Woods Capital Investors LLC increased its stake in Amgen Inc. by 21.0% in the first quarter, adding 4,003 shares to its portfolio, now owning 23,064 shares valued at $8.115 million. Other institutional investors also adjusted their holdings in Amgen, which constitutes about 1.9% …

Amgen Finds No Material Impact From Cybersecurity Incident

Amgen has reported that a recent cybersecurity incident resulted in the exfiltration of proprietary data and patient health information. However, the company has concluded that this breach will not have a material impact on its operations. This statement comes amidst several recent news items …

Amgen discloses data breach, says patient information was stolen

Drugmaker Amgen announced a data breach affecting patient health information stored in third-party cloud systems. The company deemed the incident material on July 29th and has initiated its cybersecurity response plan, including engaging independent forensic experts for investigation.

Amgen Stock Leads 3 Cardiovascular Pharma Picks After Novo Nordisk Trial Miss

Following Novo Nordisk's failed late-stage heart drug trial, attention has shifted to other pharmaceutical companies with strong cardiovascular pipelines. This article highlights Amgen (AMGN), Pfizer Limited (NSEI:PFIZER), and Sanofi (ENXTPA:SAN) as potential beneficiaries. Each company is analyzed for its existing cardiovascular portfolio, growth prospects, …

Vestor Capital LLC Invests $3.26 Million in Amgen Inc. $AMGN

Vestor Capital LLC has invested $3.26 million in Amgen Inc. by purchasing 9,269 shares during the first quarter. Amgen reported strong quarterly earnings, beating estimates with $5.15 per share and a 5.8% increase in revenue. Despite mixed analyst sentiment and competition in the weight-loss …

6,407 Shares in Amgen Inc. $AMGN Bought by January Capital Advisors LLC

January Capital Advisors LLC has acquired a new position of 6,407 shares in Amgen Inc. (NASDAQ:AMGN), valued at approximately $2.25 million, making it their seventh-largest holding. Amgen recently reported strong quarterly earnings, beating analyst estimates with $5.15 EPS and revenue of $8.62 billion, and …

Janus Henderson Group PLC Sells 1,215,634 Shares of Amgen Inc. $AMGN

Janus Henderson Group PLC significantly reduced its stake in Amgen Inc. by selling 1,215,634 shares, decreasing its holdings by 52.3% in the first quarter. Despite this, other hedge funds increased their positions in Amgen, indicating mixed institutional sentiment. The article also highlights recent positive …

FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD

Amgen has launched its first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), a two-year commitment to foster scientific innovation through AI-enabled research in healthcare and drug discovery. The inaugural cohort includes 10 undergraduate scholars from various …

How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration

Amgen (AMGN) recently declared a Q3 2026 dividend of US$2.52 per share and received a positive opinion from the European Medicines Agency's CHMP for expanding Repatha's use in high-risk cardiovascular prevention. This article discusses how these developments, particularly the Repatha expansion, could influence Amgen's …